← All trials
NCT05128773
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 29, 2021
- Primary completion
- Dec 27, 2026
- Completion date
- Dec 27, 2033
- First posted
- Nov 22, 2021
- Last posted
- Nov 22, 2021
- Enrollment
- 3738
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- SanofiLead sponsor
- University of MilanCollaborator
- SanofiStudy director
- European Organisation for Research and Treatment of CancerCollaborator
- National Cancer Institute (NCI)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.